MedTrace Logo

Multicenter Study Using IMC to Analyze the Impact of ICANS on Microglia

NCT05811117 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2023-05-16

No results posted yet for this study

Summary

Immunotherapy with chimeric antigen receptor (CAR) T cell therapy can cause immune effector cell-associated neurotoxicity syndrome (ICANS). However, the molecular mechanisms leading to ICANS are not well understood. In this study, the investigators plan to examine the role of microglia as the primary parenchymal immune cells of the central nervous system (CNS) during ICANS in human samples. The samples will be analyzed using imaging-mass-cytometry-based analysis (IMC). Single-cell data will be obtained through machine learning supervised segmentation of IMC data. Single-cell marker expression in all cells and in microglia (Iba1+ cells) will be analyzed in patients with ICANS.

Conditions

  • ICANS, Grade Unspecified
  • CAR T-Cell-Related Encephalopathy Syndrome

Interventions

DIAGNOSTIC_TEST

There will be no intervention as we will study patients that undergo autopsy after CAR T cell infusion.

We will study patients that undergo autopsy after CAR T cell infusion.

Sponsors & Collaborators

  • University of Freiburg

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2023-04-05
Completion
2023-04-05

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05811117 on ClinicalTrials.gov